CE7R-modified autologous CD8+ T cells

CE7R-modified autologous CD8+ T cells is a first-generation chimeric antigen receptor (CAR) T cell therapy developed by the Fred Hutchinson Cancer Center for the treatment of pediatric patients with recurrent or refractory neuroblastoma. The therapy utilizes a patient's own CD8+ T cells, which are genetically engineered to express the CE7R chimeric receptor. This receptor targets the L1-CAM (CD171) epitope, which is highly expressed on neuroblastoma cells. The construct includes a CD3ζ intracellular signaling domain and a HyTK selection-suicide fusion protein, the latter of which allows for the ablation of the CAR T cells using ganciclovir in the event of severe toxicity.

Other names

L1-CAM-specific CAR T cellsL-1-CAM-specific CAR T cellsL 1-CAM-specific CAR T cellsCE7R-modified T cellsCE-7R-modified T cellsCE 7R-modified T cells